Payment overview · 2025
General Payments
$206.09
11 reported records · 7 companies
Healthcare provider profile · identity verified
Kenneth Grier, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · APPLE VALLEY, CA · NPI 1114235744
Verified facts
What the public records show
CMS Open Payments records show Kenneth Grier, M.D. received $206.09 in general payments during 2025 across 11 reported records.
Lilly USA, LLC accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.73 | 26.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.07 | 20.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.78 | 14.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.82 | 11.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.62 | 10.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.88 | 9.2% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $16.19 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.09 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $74.55 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.78 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| Respiratory Normalized: respiratory |
Device | Philips North America LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 81 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 344 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 342 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 80 |
| Lisinopril | Lisinopril | 239 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 231 | 85 |
| Gabapentin | Gabapentin | 213 | 81 |
| Metformin Hcl | Metformin Hcl | 172 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 59 |
| Furosemide | Furosemide | 162 | 72 |
| Losartan Potassium | Losartan Potassium | 142 | 53 |
| Eliquis | Apixaban | 137 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 66 |
| Omeprazole | Omeprazole | 127 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 46 |
| Potassium Chloride | Potassium Chloride | 123 | 49 |
| Montelukast Sodium | Montelukast Sodium | 118 | 53 |
| Famotidine | Famotidine | 110 | 47 |
| Glipizide | Glipizide | 110 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 42 |
| Simvastatin | Simvastatin | 99 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 30 |
| Trazodone Hcl | Trazodone Hcl | 97 | 40 |
| Carvedilol | Carvedilol | 88 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 42 |
| Jardiance | Empagliflozin | 81 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 23 |
| Sertraline Hcl | Sertraline Hcl | 79 | 26 |
| Ibuprofen | Ibuprofen | 67 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 25 |
| Donepezil Hcl | Donepezil Hcl | 65 | 18 |
| Nifedipine Er | Nifedipine | 63 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 31 |
| Alprazolam | Alprazolam | 54 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 17 |
| Methylprednisolone | Methylprednisolone | 49 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 11 |
| Tramadol Hcl | Tramadol Hcl | 47 | 23 |
| Azithromycin | Azithromycin | 46 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 38 |
| Lactulose | Lactulose | 44 | 22 |
| Atenolol | Atenolol | 42 | 13 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 12 |
| Meclizine Hcl | Meclizine Hcl | 38 | 17 |
| Temazepam | Temazepam | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 24 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Baclofen | Baclofen | 36 | 18 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 14 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | 17 |
| Ozempic | Semaglutide | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 19 |
| Finasteride | Finasteride | 30 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 25 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 14 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 15 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 19 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 16 |
| Diazepam | Diazepam | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 12 |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | 12 |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Aviane | Levonorgestrel/Ethin.Estradiol | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.09 · 11 records | Lilly USA, LLC | BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, MOUNJARO, Respiratory, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error